Atlas Trials

Mechanism of PERK - eIF2a Pathways in Intestinal Mucosal Barrier of IBS-D and the Role "Metabolism Ingredients" of Tongxieyaofang

Clinical trial NCT04122586 · UNKNOWN

Trial details

NCT number
NCT04122586
Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
IBS (Irritable Bowel Syndrome)
Start date
2018-08-01
Primary completion
2020-12-31
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.